Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes (Q34642403)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes (English)

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

0 references

Michelle A Fanale

3

object named as

Michelle Fanale

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Sattva S Neelapu

7

object named as

Sattva Neelapu

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

8

object named as

Larry Kwak

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Peter J McLaughlin

4

object named as

Peter McLaughlin

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Jorge Romaguera

2

object named as

Jorge Romaguera

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Fredrick B Hagemeister

5

object named as

Frederick Hagemeister

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

1

object named as

Anas Younes

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Amanda R Copeland

6

object named as

Amanda Copeland

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Silvana de Castro Faria

10

object named as

Silvana de Castro Faria

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

author name string

Jatin Shah

9

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Stefan Hart

11

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Jeanette Wood

12

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Ramesh Jayaraman

13

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Kantharaj Ethirajulu

14

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Joy Zhu

15

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

language of work or name

0 references

publication date

10 September 2012

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

30

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

33

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

4161-4167

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

The Jak/STAT pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Targeting the interleukin-6/Jak/stat pathway in human malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Dynamics and non-canonical aspects of JAK/STAT signalling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) [...]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

SOCS regulation of the JAK/STAT signalling pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

The JAK-STAT signaling pathway: input and output integration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

JAK/STAT signal transduction: regulators and implication in hematological malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Cytokines in malignant lymphomas: review and prospective evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Activation of cytokines in Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

7 July 2018

Revised response criteria for malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

26 October 2018

STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

9 December 2018

Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5950499

9 December 2018

Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term outcome of treatment with ruxolitinib in myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proangiogenic cytokines produced by non-Hodgkin lymphoma tumor cells induce angiogenesis in infiltrated bone marrow samples

1 reference

https://pubmed.ncbi.nlm.nih.gov/22965964

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2012.42.5223

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 June 2018

http://europepmc.org/abstract/PMC/5950499

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34642403&oldid=2138091825"